|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,400 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Clinical Trials for: ABRAXANE
First 100 trials shown — repeat this search at ClinicalTrials.gov| Title | Status | Condition | Last Changed | External link |
|---|---|---|---|---|
| Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer | Recruiting | Bladder Cancer | November 2, 2012 | link |
| Hepatic Arterial Infusion (HAI) of Abraxane | Active, not recruiting | Liver Cancer; Advanced Cancers; Solid Tumors | October 23, 2012 | link |
| Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer) | Completed | Brenner Tumor; Fallopian Tube Cancer; Ovarian Carcinosarcoma; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer | March 18, 2013 | link |
| Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) | Active, not recruiting | HEAD & NECK Cancer | January 31, 2013 | link |
| Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer | Terminated | Breast Neoplasms; Neoplasm Metastasis | March 19, 2012 | link |
| Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma | Recruiting | Lymphoma, Non-Hodgkin; Hodgkin Disease | May 6, 2013 | link |
| Pazopanib (VOTRIENT) Plus Paclitaxel (TAXOL), Pazopanib Plus Paclitaxel (TAXOL) Plus Carboplatin (PARAPLATIN), and Pazopanib Plus Paclitaxel (TAXOL) Plus Lapatinib (TYKERB) | Completed | Solid Tumor Cancer; Neoplasms, Breast | March 15, 2012 | link |
| Study Comparing Nanoparticle-based Paclitaxel With Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Patients With Early Breast Cancer (GeparSepto) | Recruiting | Tubular Breast Cancer Stage II; Mucinous Breast Cancer Stage II; Breast Cancer Female NOS; Invasive Ductal Breast Cancer; Tubular Breast Cancer Stage III; HER-2 Positive Breast Cancer; Inflammatory Breast Cancer Stage IV; Inflammatory Breast Cancer | July 30, 2012 | link |
| Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours | Recruiting | Neoplasms | June 12, 2013 | link |
| Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer | Active, not recruiting | Breast Cancer; Triple Negative Breast Cancer; Stage IV Breast Cancer; Metastatic Breast Cancer | February 11, 2013 | link |
| A Phase I/II Study of Nab-Paclitaxel, or Paclitaxel, Plus Carboplatin With Concurrent Radiation Therapy Followed by Consolidation in Patients With Favorable Prognosis Inoperable Stage IIIA/B NSCLC | Recruiting | INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER | March 25, 2013 | link |
| Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer | Recruiting | Male Breast Cancer; Recurrent Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer | September 3, 2012 | link |
| Bevacizumab and Abraxane as Second-line Therapy in Triple Negative Metastatic Breast Cancer | Completed | Breast Cancer | January 31, 2013 | link |
| Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers | Completed | Advanced Cancers | January 21, 2013 | link |
| Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer | Active, not recruiting | Breast Cancer | August 6, 2012 | link |
| Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas | Recruiting | Colorectal Cancer; Cancer of Gastrointestinal Tract | May 21, 2013 | link |
| Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer | Completed | Neoplasm | June 30, 2011 | link |
| Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer | Active, not recruiting | Urothelial Cancer; Bladder Cancer | May 11, 2013 | link |
| Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma | Recruiting | Melanoma | April 25, 2013 | link |
| Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer | Active, not recruiting | Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Recurrent Esophageal Cancer; Squamous Cell Carcinoma of the Esophagus; Stage IV Esophageal Cancer | March 18, 2013 | link |
| Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver | Active, not recruiting | Melanoma; Liver Metastasis | February 26, 2013 | link |
| Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer | Recruiting | Breast Cancer | July 24, 2012 | link |
| Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma | Completed | Melanoma | December 31, 2012 | link |
| Efficacy & Safety of ODSH (2-0, 3-0 Desulfated Heparin) in Patients With Metastatic Pancreatic Cancer Treated With Gemcitabine & Abraxane | Recruiting | Metastatic Pancreatic Cancer | November 9, 2012 | link |
| Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown Primary | Completed | Occult Primary | January 28, 2013 | link |
| PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer | Recruiting | Metastatic Pancreatic Cancer | June 11, 2013 | link |
| HAI Abraxane With Gemcitabine and Bevacizumab | Recruiting | Advanced Cancers | March 29, 2013 | link |
| Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer | Recruiting | Breast Cancer | January 4, 2013 | link |
| BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors | Recruiting | Solid Tumors | April 18, 2013 | link |
| Dose Dense Abraxane in Adjuvant Chemotherapy for Breast Cancer | Completed | Breast Cancer | February 15, 2013 | link |
| Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery for Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | Completed | Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage II Ovarian Epithelial Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer | March 18, 2013 | link |
| Abraxane and Alimta in Advanced Solid Tumors | Active, not recruiting | Breast Cancer; Lung Cancer; Unspecified Adult Solid Tumor, Protocol Specific | March 28, 2013 | link |
| Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | Recruiting | Esophageal Cancer | October 10, 2012 | link |
| A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers | Recruiting | Advanced Solid Cancers | June 5, 2009 | link |
| Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer | Not yet recruiting | Pancreatic Adenocarcinoma Resectable; Pancreatic Adenocarcinoma Locally Advanced; Pancreatic Adenocarcinoma Metastatic | October 24, 2012 | link |
| Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma | Completed | Pancreatic Neoplasms; Pancreatic Cancer; Adenocarcinoma | October 10, 2012 | link |
| Trial of Paclitaxel/Bevacizumab +/- Everolimus for Patients With HER2-Negative Metastatic Breast Cancer | Active, not recruiting | Metastatic Breast Cancer | January 31, 2013 | link |
| Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients | Recruiting | Advanced or Metastatic Breast Cancer,; ER+ve Advanced or Metastatic Breast Cancer. | May 8, 2013 | link |
| Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC) | Recruiting | Metastatic Breast Cancer | December 3, 2012 | link |
| Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 | Recruiting | Breast Cancer | May 16, 2013 | link |
| Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis | Completed | Coronary Restenosis | March 28, 2012 | link |
| Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer | Active, not recruiting | Breast Cancer | August 20, 2012 | link |
| A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer | Recruiting | Head and Neck Cancer | June 12, 2012 | link |
| A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | Terminated | Breast Cancer | May 9, 2012 | link |
| A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy | Recruiting | Stage IV Gastric Cancer | May 2, 2013 | link |
| Schedules of Nab-Paclitaxel in Metastatic Breast Cancer | Recruiting | Metastatic Breast Cancer. | May 10, 2013 | link |
| Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | Terminated | Carcinoma, Non-Small-Cell Lung | September 24, 2009 | link |
| Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | Active, not recruiting | Metastatic Melanoma | March 20, 2013 | link |
| Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer | Active, not recruiting | Small Cell Lung Cancer | February 1, 2013 | link |
| A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer | Completed | Metastatic Breast Cancer | August 5, 2012 | link |
| MLN8237 in Patients With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | Recruiting | Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Cancer; Breast Carcinoma | January 23, 2013 | link |
| A Phase I/II Clinical Trial of Vidaza With Abraxane in the Treatment of Patients With Advanced or Metastatic Solid Tumors and Breast Cancer | Recruiting | Advanced or Metastatic Solid Tumors; Advanced or Metastatic Breast Cancer | April 10, 2013 | link |
| Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer | Recruiting | Metastatic Breast Cancer | December 28, 2012 | link |
| Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer | Completed | Metastatic Pancreatic Cancer | February 28, 2013 | link |
| Assessment Of Stromal Response To Nab-Paclitaxel In Combination With Gemcitabine In Pancreatic Cancer | Completed | Pancreatic Cancer | March 12, 2013 | link |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cancer, or Fallopian Tube Cancer | Active, not recruiting | Brenner Tumor; Fallopian Tube Cancer; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mixed Epithelial Carcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Ovarian Undifferentiated Adenocarcinoma; Primary Peritoneal Cavity Cancer; Stage III Ovarian Epithelial Cancer; Stage IV Ovarian Epithelial Cancer | September 19, 2012 | link |
| A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma | Active, not recruiting | Malignant Melanoma | May 11, 2012 | link |
| Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer | Active, not recruiting | Resectable Pancreatic Cancer | May 1, 2013 | link |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | Active, not recruiting | Endometrial Adenocarcinoma; Endometrial Adenosquamous Cell Carcinoma; Endometrial Clear Cell Carcinoma; Recurrent Endometrial Carcinoma; Stage III Endometrial Carcinoma; Stage IV Endometrial Carcinoma | June 11, 2013 | link |
| Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer | Active, not recruiting | Male Breast Cancer; Recurrent Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer | April 10, 2013 | link |
| Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either Abraxane or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer | Completed | Breast Cancer | May 3, 2010 | link |
| A Study of Ramucirumab and Paclitaxel in Patients With Solid Tumors | Active, not recruiting | Malignant Solid Tumor | March 27, 2013 | link |
| Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity | Recruiting | Ovarian Cancer; Peritoneal Cavity Cancer; Unspecified Adult Solid Tumor, Protocol Specific | March 20, 2013 | link |
| Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer | Recruiting | Breast Cancer | December 28, 2012 | link |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recruiting | Refractory Multiple Myeloma | March 13, 2013 | link |
| Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer | Active, not recruiting | Breast Cancer | April 21, 2013 | link |
| Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | Active, not recruiting | Squamous Cell Carcinoma of the Head and Neck; Basaloid Squamous Cell Carcinoma; Undifferentiated Carcinoma; Adenosquamous Cell Carcinoma | February 28, 2013 | link |
| ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer | Completed | Breast Cancer | May 31, 2011 | link |
| Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer | Completed | Prostate Cancer | September 28, 2012 | link |
| Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | Recruiting | Triple Negative Breast Cancer | April 29, 2013 | link |
| Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer | Terminated | Prostatic Neoplasms | January 30, 2009 | link |
| PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | Completed | Ovarian Cancer; Peritoneal Cancer; Fallopian Tube Cancer | December 27, 2012 | link |
| Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | Recruiting | Breast Cancer | April 3, 2012 | link |
| Therapy With Abraxane and 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) for Patients With Breast Cancer | Completed | Breast Neoplasms | March 24, 2010 | link |
| Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxaneâ„¢) | Completed | Breast Cancer | June 16, 2012 | link |
| M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Recruiting | Metastatic Pancreatic Cancer | June 6, 2013 | link |
| Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study | Completed | Metastatic Malignant Melanoma | October 27, 2012 | link |
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | Completed | Neoplasms, Gastrointestinal Tract | January 4, 2013 | link |
| Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients | Completed | Gastric Cancer | November 19, 2012 | link |
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer | Active, not recruiting | Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Recurrent Cervical Cancer; Stage IVB Cervical Cancer | March 11, 2013 | link |
| Phase II NCT w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast Cancer | Active, not recruiting | Breast Cancer | May 22, 2012 | link |
| Phase II, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas | Recruiting | Adenocarcinoma Pancreas | January 31, 2013 | link |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Metastatic Solid Tumors | Completed | Unspecified Adult Solid Tumor, Protocol Specific | March 5, 2012 | link |
| Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma | Active, not recruiting | Mucosal Melanoma; Recurrent Melanoma; Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IV Melanoma | June 4, 2013 | link |
| Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | Active, not recruiting | Uterine Cancer | September 26, 2012 | link |
| Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II) | Active, not recruiting | Neoplasms; Breast Neoplasms; Breast Cancer | March 5, 2013 | link |
| Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | Recruiting | Stage I Bladder Cancer; Stage II Bladder Cancer; Stage III Bladder Cancer; Transitional Cell Carcinoma of the Bladder | March 18, 2013 | link |
| Topical Imiquimod and Abraxane in Treating Patients With Advanced Breast Cancer | Active, not recruiting | Male Breast Cancer; Recurrent Breast Cancer; Skin Metastases; Stage IV Breast Cancer | May 22, 2013 | link |
| A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma | Completed | Malignant Melanoma | May 2, 2012 | link |
| A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without Trastuzumab | Active, not recruiting | Metastatic or Locally Advanced Solid Tumors, | May 15, 2013 | link |
| ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer | Completed | Metastatic Breast Cancer | April 3, 2013 | link |
| Study of Albumin Bound-Paclitaxel for Treatment of Recurrent or Metastatic Head and Neck Cancer With Cetuximab | Active, not recruiting | Head and Neck Cancer | January 13, 2010 | link |
| Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC | Active, not recruiting | Neoplasms, Breast | January 21, 2013 | link |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | Recruiting | Recurrent Non-small Cell Lung Cancer; Stage IV Non-small Cell Lung Cancer | December 26, 2012 | link |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery | Recruiting | Adenocarcinoma of the Lung; Adenosquamous Cell Lung Cancer; Bronchoalveolar Cell Lung Cancer; Large Cell Lung Cancer; Squamous Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer | May 6, 2013 | link |
| Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Recruiting | Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer | February 5, 2013 | link |
| Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer | Completed | Breast Cancer | July 5, 2012 | link |
| Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer | Recruiting | Pancreatic Cancer | September 21, 2012 | link |
| Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer | Terminated | Metastatic, Gastric or Gastro-oesophageal Junction, Cancer | March 22, 2013 | link |
| Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE) | Completed | Breast Cancer | August 29, 2011 | link |
Source: ClinicalTrials.gov
This preview shows a limited data set. Complete access is available with a Subscription
« Back to Dashboard
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc
